Description: Dapatorq 10 contains Dapagliflozin is a highly potent, selective and reversible inhibitor of SGLT2.
Dosage Form: Tablets
Route of Administration: Oral
Composition: Each lm coated tablet contains:
Dapagliflozin Propanediol USP
Eq. to Dapagliflozin 10 mg
Excipients q.s.
Mechanism of Action: Dapagliflozin inhibits SGLT2 thus reduces reabsorption of glucose from the glomerular filtrate in the proximal renal tubule with a concomitant reduction in sodium reabsorption leading to urinary excretion of glucose and osmotic diuresis. Dapagliflozin improves both fasting and post-prandial plasma glucose levels.
Indications: Dapatorq 10 is indicated for the treatment of patients with type II diabetes mellitus when diet, exercise and single agent does not result in adequate glycemic control.
Dosage: As directed by the physician.
Side effects: The following adverse reactions may occur: Genital Infections, Urinary Tract Infection, Hypoglycaemia, Dizziness, Rash, Back Pain, Dysuria, Polyuria, Dyslipidaemia, Ketoacidosis
Contraindications: Dapatorq 10 is contraindicated in patients with known hypersensitivity to Dapagliflozin or any of the components of this product. Severe renal impairment (eGFR less than 30 mL/min/1.73 m2) in patients who are being treated for glycemic control without established cardiovascular disease or cardiovascular risk factors. Patients on dialysis.
Drug Interactions: Diuretics, Rifampicin, Mefenamic Acid
Storage: Store protected from light & moisture, at a temperature not exceeding 30°C.
Presentation: 20 x 15